Obicetrapib and cardiovascular events | JACC | ESC25

JACC covers the latest science at ESC 2025 in this video interview with Neha J Pagidipati, MD, FACC and Stephen J. Nicholls, MBBS, PhD, FACC. The study, published in JACC and presented at ESC, discusses obicetrapib, a highly selective cholesteryl ester transfer protein inhibitor which lowers LDL-C and Lp(a) and raises HDL-C. This pooled analysis of trials investigating the lipid effects of 12 months of treatment with obicetrapib in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia examined its effects on cardiovascular events. A lower rate of coronary heart disease death, myocardial infarction and coronary revascularization was observed with obicetrapib. Achieved levels of LDL-C, apoB, HDL-C, non-HDL-C and Lp(a) associated with the rate of cardiovascular events, requiring further exploration. This highlights the potential of obicetrapib to reduce cardiovascular risk.